Skip to main content
PMC home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2009 Jun;70(3):185–196. doi: 10.1016/j.curtheres.2009.05.004

The efficacy and tolerability of glucosamine sulfate in the treatment of knee osteoarthritis: A randomized, double-blind, placebo-controlled trial

Nicola Giordano 1,*, Antonella Fioravanti 2, Panagiotis Papakostas 1, Antonio Montella 1, Giorgio Giorgi 3, Ranuccio Nuti 1
PMCID: PMC3967292  PMID: 24683229

Abstract

Background: Osteoarthritis (OA) is the most common form of arthritis and is often associated with disability and impaired quality of life.

Objective: The aim of the study was to assess the efficacy and tolerability of glucosamine sulfate (GS) in the treatment of knee OA.

Methods: Consecutive outpatients affected by primary monolateral or bilateral knee OA were enrolled in this double-blind, double-dummy, prospective, randomized, placebo-controlled trial. One group received GS 1500 mg QD for 12 weeks, and the other group received placebo QD for 12 weeks. The treatment period was followed by a 12-week treatment-free observation phase. Each patient was examined at baseline and at weeks 4, 8, 12, 16, 20, and 24. The primary efficacy criteria were pain at rest and during movement, assessed on a visual analog scale (VAS) of 0 to 100 mm. The secondary criteria included the Western Ontario and McMaster Universities (WOMAC) index for total pain score (W-TPS), total stiffness score (W-TSS), and total physical function score (W-TPFS). VAS, W-TPS, W-TSS, and W-TPFS were evaluated at baseline and at weeks 4, 8, 12, 16, 20, and 24. Analgesic drug consumption (ie, acetaminophen or NSAIDs) was also assessed.

Results: Patient demographics were similar in the GS and placebo groups. Of 60 randomized patients (30 per group), 56 completed the study (28 treated with GS and 28 who received placebo). Statistically significant improvements in symptomatic knee OA were observed, as measured by differences in resting pain at weeks 8, 12, and 16 (all, P < 0.05 vs placebo) and in pain during movement at weeks 12 and 16 (both, P < 0.05). W-TPS was lower with GS than placebo at weeks 8, 12, and 16 (all, P < 0.01), and at week 20 (P < 0.05). W-TSS was also lower with GS than placebo at weeks 8, 12, 16, and 20 (all, P < 0.05). W-TPFS was lower with GS than placebo at weeks 8 (P < 0.05), 12 (P < 0.01), 16 (P < 0.05), and 20 (P < 0.05). Drug consumption was lower in the GS group than the placebo group at weeks 8, 12, 16, and 20 (all, P < 0.05). The incidence of adverse events was 36.7% with GS and 40.0% with placebo.

Conclusions: GS 1500 mg QD PO for 12 weeks was associated with statistically significant reductions in pain and improvements in functioning, with decreased analgesic consumption, compared with baseline and placebo in these patients with knee OA. A carryover effect was detected after treatment ended.

Key words: glucosamine sulfate, knee osteoarthritis, efficacy, carryover effect, tolerability

Full Text

The Full Text of this article is available as a PDF (119.4 KB).

References

  • 1.Peat G, McCarney R, Croft P. Knee pain and osteoarthritis in older adults: Review of community burden and current use of primary health care. Ann Rheum Dis. 2001;60:91–97. doi: 10.1136/ard.60.2.91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Jordan KM, Arden NK, Doherty M, the Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT EULAR Recommendations 2003: An evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT) Ann Rheum Dis. 2003;62:1145–1155. doi: 10.1136/ard.2003.011742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Ofman JJ, Maclean CH, Straus WL. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol. 2002;29:804–812. [PubMed] [Google Scholar]
  • 4.Huskisson EC, Berry H, Gishen P, the LINK Study Group (Longitudinal Investigation of Nonsteroidal Antiinflammatory Drugs in Knee Osteoarthritis) Effects of antiinflammatory drugs on the progression of osteoarthritis of the knee. J Rheumatol. 1995;22:1941–1946. [PubMed] [Google Scholar]
  • 5.Bresalier RS, Sandler RS, Quan H, the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [published correction appears in N Engl J Med. 2006;355:221] N Engl J Med. 2005;352:1092–1102. doi: 10.1056/NEJMoa050493. [DOI] [PubMed] [Google Scholar]
  • 6.Kearney PM, Baigent C, Godwin J. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Metaanalysis of randomised trials. BMJ. 2006;332:1302–1308. doi: 10.1136/bmj.332.7553.1302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis. 2004;63:901–907. doi: 10.1136/ard.2003.018531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Pincus T, Wang X, Chung C. Patient preference in a crossover clinical trial of patients with osteoarthritis of the knee or hip: Face validity of self-report questionnaire ratings [published correction appears in J Rheumatol. 2005;32:966] J Rheumatol. 2005;32:533–539. [PubMed] [Google Scholar]
  • 9.Brandt KD. Toward pharmacologic modification of joint damage in osteoarthritis. Ann Intern Med. 1995;122:874–875. doi: 10.7326/0003-4819-122-11-199506010-00011. [DOI] [PubMed] [Google Scholar]
  • 10.Richette P, Bardin T. Structure-modifying agents for osteoarthritis: An update. Joint Bone Spine. 2004;71:18–23. doi: 10.1016/S1297-319X(03)00129-5. [DOI] [PubMed] [Google Scholar]
  • 11.Verbruggen G. Chondroprotective drugs in degenerative joint diseases. Rheumatology (Oxford) 2006;45:129–138. doi: 10.1093/rheumatology/kei171. [DOI] [PubMed] [Google Scholar]
  • 12.Altman R, Brandt K, Hochberg M. Design and conduct of clinical trials in patients with osteoarthritis: Recommendations from a task force of the Osteoarthritis Research Society: Results from a workshop. Osteoarthritis Cartilage. 1996;4:217–243. doi: 10.1016/s1063-4584(05)80101-3. [DOI] [PubMed] [Google Scholar]
  • 13.Group for the Respect of Ethics and Excellence in Science (GREES): Osteoarthritis Section Recommendations for the registration of drugs used in the treatment of osteoarthritis. Ann Rheum Dis. 1996;55:552–557. doi: 10.1136/ard.55.8.552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Noyszewski EA, Wroblewski K, Dodge GR. Preferential incorporation of glucosamine into the galactosamine moieties of chondroitin sulfates in articular cartilage explants. Arthritis Rheum. 2001;44:1089–1095. doi: 10.1002/1529-0131(200105)44:5<1089::AID-ANR189>3.0.CO;2-9. [DOI] [PubMed] [Google Scholar]
  • 15.Bassleer C, Rovati L, Franchimont P. Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro. Osteoarthritis Cartilage. 1998;6:427–434. doi: 10.1053/joca.1998.0146. [DOI] [PubMed] [Google Scholar]
  • 16.Varghese S, Theprungsirikul P, Sahani S. Glucosamine modulates chondrocyte proliferation, matrix synthesis, and gene expression. Osteoarthritis Cartilage. 2007;15:59–68. doi: 10.1016/j.joca.2006.06.008. [DOI] [PubMed] [Google Scholar]
  • 17.Dodge GR, Jimenez SA. Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritis articular chondrocytes. Osteoarthritis Cartilage. 2003;11:424–432. doi: 10.1016/s1063-4584(03)00052-9. [DOI] [PubMed] [Google Scholar]
  • 18.Conrozier T, Mathieu P, Piperno M. Glucosamine sulfate significantly reduced cartilage destruction in a rabbit model of osteoarthritis. Arthritis Rheum. 1998;41(Suppl):147. [Google Scholar]
  • 19.Largo R, Alvarez-Soria MA, Díez-Ortego I. Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage. 2003;11:290–298. doi: 10.1016/s1063-4584(03)00028-1. [DOI] [PubMed] [Google Scholar]
  • 20.Chan PS, Caron JP, Rosa GJ, Orth MW. Glucosamine and chondroitin sulfate regulate gene expression and synthesis of nitric oxide and prostaglandin E(2) in articular cartilage explants. Osteoarthritis Cartilage. 2005;13:387–394. doi: 10.1016/j.joca.2005.01.003. [DOI] [PubMed] [Google Scholar]
  • 21.Rovati LC, Poma A, Biavati G. A multicenter, randomized, double-blind, parallel-group study to investigate efficacy and safety of oral glucosamine sulfate in osteoarthritis of the spine. Rotthapharm; Milan, Italy: 1993. [Google Scholar]
  • 22.Noack W, Fisher M, Förster KK. Glucosamine sulfate in osteoarthritis of the knee. Osteoarthritis Cartilage. 1994;2:51–59. doi: 10.1016/s1063-4584(05)80006-8. [DOI] [PubMed] [Google Scholar]
  • 23.McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: A systematic quality assessment and meta-analysis. JAMA. 2000;283:1469–1475. doi: 10.1001/jama.283.11.1469. [DOI] [PubMed] [Google Scholar]
  • 24.Towheed TE, Maxwell L, Anastassiades TP. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005;2:CD002946. doi: 10.1002/14651858.CD002946.pub2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: A randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum. 2007;56:555–567. doi: 10.1002/art.22371. [DOI] [PubMed] [Google Scholar]
  • 26.Reginster JY, Deroisy R, Rovati LC. Long-term effects of glucosamine sulphate on osteoarthritis progression: A randomised, placebo-controlled clinical trial. Lancet. 2001;357:251–256. doi: 10.1016/S0140-6736(00)03610-2. [DOI] [PubMed] [Google Scholar]
  • 27.Pavelká K, Gatterová J, Olejarová M. Glucosamine sulfate use and delay of progression of knee osteoarthritis: A 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2002;162:2113–2123. doi: 10.1001/archinte.162.18.2113. [DOI] [PubMed] [Google Scholar]
  • 28.Clegg DO, Reda DJ, Harris CL. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354:795–808. doi: 10.1056/NEJMoa052771. [DOI] [PubMed] [Google Scholar]
  • 29.Rozendaal RM, Koes BW, van Osch GJ. Effect of glucosamine sulfate on hip osteoarthri-tis: A randomized trial. Ann Intern Med. 2008;148:268–277. doi: 10.7326/0003-4819-148-4-200802190-00005. [DOI] [PubMed] [Google Scholar]
  • 30.Altman R, Asch E, Bloch D, the Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum. 1986;29:1039–1049. doi: 10.1002/art.1780290816. [DOI] [PubMed] [Google Scholar]
  • 31.Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957;16:494–502. doi: 10.1136/ard.16.4.494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Dougados M, Leclaire P, van der Heijde D. Response criteria for clinical trials on osteoar-thritis of the knee and hip: A report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative. Osteoarthritis Cartilage. 2000;8:395–403. doi: 10.1053/joca.2000.0361. [DOI] [PubMed] [Google Scholar]
  • 33.Bellamy N, Goldsmith CH, Buchanan WW. Prior score availability: Observations using the WOMAC osteoarthritis index. Br J Rheumatol. 1991;30:150–151. doi: 10.1093/rheumatology/30.2.150. [DOI] [PubMed] [Google Scholar]
  • 34.Salaffi F, Leardini G, Canesi B, the GOnorthrosis and Quality Of Life Assessment (GOQOLA) Reliability and validity of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index in Italian patients with osteoarthritis of the knee. Osteoarthritis Cartilage. 2003;11:551–560. doi: 10.1016/s1063-4584(03)00089-x. [DOI] [PubMed] [Google Scholar]
  • 35.Rovati LC. The clinical profile of glucosamine sulfate as a selective symptom modifying drug in osteoarthritis: Current data and perspectives. Osteoarthritis Cartilage. 1997;5:72. [Google Scholar]
  • 36.Persiani S, Roda E, Rovati LC. Glucosamine oral bioavailability and plasma pharmaco-kinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis Cartilage. 2005;13:1041–1049. doi: 10.1016/j.joca.2005.07.009. [DOI] [PubMed] [Google Scholar]
  • 37.Persiani S, Rotini R, Trisolino G. Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. Osteoarthritis Cartilage. 2007;15:764–772. doi: 10.1016/j.joca.2007.01.019. [DOI] [PubMed] [Google Scholar]
  • 38.Jackson CG, Plaas AH, Barnhill JG. The pharmacokinetics of oral glucosamine and chondroitin sulphate in human. Arthritis Rheum. 2005;52:4062–4063. [Google Scholar]
  • 39.Hoffer LJ, Kaplan LN, Hamadeh MJ. Sulfate could mediate the therapeutic effect of glucosamine sulfate. Metabolism. 2001;50:767–770. doi: 10.1053/meta.2001.24201. [DOI] [PubMed] [Google Scholar]
  • 40.Baron AD, Zhu JS, Zhu JH. Glucosamine induces insulin resistance in vivo by affecting GLUT 4 translocation in skeletal muscle. Implication for glucose toxicity. J Clin Invest. 1995;96:2792–2801. doi: 10.1172/JCI118349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Cannon GW, Caldwell JR, Holt P, the Rofecoxib Phase III Protocol 035 Study Group Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomized, clinical trial in patients with osteoar-thritis of the knee and hip. Arthritis Rheum. 2000;43:978–987. doi: 10.1002/1529-0131(200005)43:5<978::AID-ANR4>3.0.CO;2-0. [DOI] [PubMed] [Google Scholar]
  • 42.Schnitzer TJ, Weaver AL, Polis AB, the VACT-1 and VACT-2 (Protocols 106 and 150) Study Groups Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthri-tis of the knee: A combined analysis of the VACT studies. J Rheumatol. 2005;32:1093–1105. [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES